CTMX

Over the past six months, CytomX Therapeutics' stock price declined by 13.79%, from $3.19 on September 30, 2025, to $2.75 on September 29, 2026, with recent trading at $2.64 on October 1, 2026, and $2.55 on October 7, 2026. On August 27, 2026, the company announced that its drug candidate Varsetatug masetecan received FDA Fast Track Designation for Relapsed/Refractory Metastatic Colorectal Cancer. On August 6, 2026, Q2 2026 financial results showed a significant revenue decline to $1.4 million, a 92.5% decrease from the prior year, due to the conclusion of collaborations, and a wider-than-expected adjusted loss of $0.09 per share. In March 2026, the stock experienced a rally followed by a fall related to colorectal cancer data. Technical indicators in late September and early October 2026 showed bearish signals, including the Momentum Indicator moving below zero, the 10-day moving average crossing below the 50-day moving average, and the MACD turning negative. Investor concerns have been noted regarding the potential toxicity profile of a lead clinical candidate, and short interest in the stock recently increased by 15.30%.